Abstracts Archive - Page 1373 of 2607 - ACR Meeting Abstracts

Abstract Number: 2802 • 2018 ACR/ARHP Annual Meeting
Risk of Ischemic Stroke in Veterans with Systemic Sclerosis: A Nationwide Cohort Study
David Ying^1,2, Milena Gianfrancesco¹, Laura Trupin¹, Jinoos Yazdany¹, Eric Greidinger^3,4 and Gabriela Schmajuk^2,5, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, San Francisco, CA, ³Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁴Miami VA Medical Center, Miami, FL, ⁵Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA
Background/Purpose: Previously thought to involve primarily the microvasculature, systemic sclerosis (SSc) has been increasingly linked to macrovascular disease. Cardiovascular and cerebrovascular disease are responsible for…
Abstract Number: 2803 • 2018 ACR/ARHP Annual Meeting
48-Year Trends in Systemic Sclerosis Mortality in the United States, 1968-2015: Steady Decrease for 15 Years after 33 Years of Continuous Increase
Eric Yen, Devanshu Singh and Ram R. Singh, UCLA, Los Angeles, CA
Background/Purpose: A comprehensive evaluation of long-term trends in systemic sclerosis (SSc) mortality is important to understand the influence of recent advances in SSc management and…
Abstract Number: 2804 • 2018 ACR/ARHP Annual Meeting
Identifying Lupus Patients in Electronic Health Records: Development and Validation of Machine Learning Algorithms and Application of Rule-Based Algorithms
April Jorge¹, Victor M. Castro², April Barnado³, Vivian Gainer², Chuan Hong⁴, Tianxi Cai², Robert Carroll⁵, Leslie Crofford³, Karen Costenbader⁶, Katherine P. Liao⁷, Elizabeth Karlson⁶ and Candace H. Feldman⁶, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Research Information Systems and Computing, Partners Healthcare, Boston, MA, ³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁴Harvard T.H. Chan School of Public Health, Boston, MA, ⁵Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: To utilize electronic health records (EHR) to study SLE, phenotypic algorithms are needed to accurately identify these patients. We aimed to generate an EHR…
Abstract Number: 2805 • 2018 ACR/ARHP Annual Meeting
Association of Dietary Quality Scores and Incident SLE in the Nurses’ Health Studies
Medha Barbhaiya¹, Bing Lu², Sara K. Tedeschi², Cianna Leatherwood³, Jeffrey A. Sparks³, Elizabeth Karlson² and Karen Costenbader³, ¹Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: High intake of antioxidants, fruits/vegetables, nuts and legumes and low intake of sodium, sweetened beverages, and red/processed meats may reduce inflammatory biomarkers and decrease…
Abstract Number: 2806 • 2018 ACR/ARHP Annual Meeting
Childhood Physical and Sexual Abuse and Risk of Systemic Lupus Erythematosus Among African American Women
Medha Barbhaiya¹, Yvette Cozier², Nelsy Castro-Webb², Sara K. Tedeschi³, Cianna Leatherwood⁴, Lynn Rosenberg² and Karen Costenbader⁴, ¹Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Slone Epidemiology Center, Boston University, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: We and others have previously reported that post-traumatic stress disorder (PTSD) is associated with increased risk of developing SLE. We aimed to investigate the…
Abstract Number: 2807 • 2018 ACR/ARHP Annual Meeting
Association of Exposure to Childhood Abuse with Incident Systemic Lupus Erythematosus in a Longitudinal Cohort of Women
Candace H. Feldman¹, Susan Malspeis², Cianna Leatherwood¹, Laura Kubzansky³, Karen Costenbader¹ and Andrea Roberts⁴, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, ⁴Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Prior studies demonstrated associations between post-traumatic stress disorder and increased risk of incident SLE and between childhood trauma and increased risk of hospitalization for…
Abstract Number: 2808 • 2018 ACR/ARHP Annual Meeting
T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
Felicia Cosman¹, E. Michael Lewiecki², Peter R Ebeling³, Eric Hesse⁴, Nicola Napoli⁵, Daria B Crittenden⁶, Maria Rojeski⁶, Wenjing Yang⁶, Cesar Libanati⁷ and Serge Ferrari⁸, ¹Columbia University, New York, NY, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Monash University, Melbourne, Australia, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Amgen Inc., Thousand Oaks, CA, ⁷UCB Pharma, Brussels, Belgium, ⁸Geneva University Hospital, Geneva, Switzerland
Background/Purpose: BMD is a strong predictor of fracture risk in untreated patients. Recent evidence suggests that BMD achieved during treatment also reflects fracture risk; thus,…
Abstract Number: 2809 • 2018 ACR/ARHP Annual Meeting
Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed
Serge Ferrari¹, E. Michael Lewiecki², Peter W. Butler³, David L Kendler⁴, Nicola Napoli⁵, Shuang Huang³, Daria B Crittenden³, Nicola Pannacciulli³, E.S. Siris⁶ and Neil Binkley⁷, ¹Geneva University Hospital, Geneva, Switzerland, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Amgen Inc., Thousand Oaks, CA, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Columbia University Medical Center, New York, NY, ⁷University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI
Background/Purpose: Osteoporosis is a chronic disease, yet skeletal safety events—atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ)—remain a concern with long-term treatment. Ten…
Abstract Number: 2810 • 2018 ACR/ARHP Annual Meeting
Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated with Abaloparatide Followed By Alendronate
Benjamin Leder¹, Carol Zapalowski², Ming-Yi Hu³ and Gary Hattersley², ¹Endocrine, Harvard Medical School, Boston, MA, ²Radius Health, Inc., Waltham, MA, ³Biometrics, Radius Health, Inc., Waltham, MA
Background/Purpose: Abaloparatide (ABL) is an anabolic PTHrP analog approved to treat postmenopausal women with osteoporosis at high risk of fracture. In the ACTIVE Phase 3…
Abstract Number: 2811 • 2018 ACR/ARHP Annual Meeting
Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older
Susan L. Greenspan¹, Lorraine A Fitzpatrick², Bruce Mitlak², Yamei Wang², Nicholas C. Harvey³, Chad Deal⁴, Felicia Cosman⁵ and Michael McClung⁶, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Radius Health, Inc., Waltham, MA, ³MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁴Cleveland Clinic, Shaker Heights, OH, ⁵Columbia University College of Physicians and Surgeons, New York, NY, ⁶Oregon Osteoporosis Center, Portland, OR
Background/Purpose: The risk of fracture increases with increasing age. Thus, it is important to understand efficacy and safety of osteoporosis treatments in elderly patients. In…
Abstract Number: 2812 • 2018 ACR/ARHP Annual Meeting
Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture
Mariana O Perez¹, Diogo S Domiciano¹, Luciene M Reis², Vanda Jorgetti² and Rosa M R Pereira¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ²Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures and subtrochanteric/diaphyseal localization that have been related to long-term bisphosphonate therapy. Patients with AFF exhibit…
Abstract Number: 2813 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism with Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Trials
Rashmi Dhital¹, Dilli Poudel², Bidhya Timilsina³, Theresa Lynn³, Colin Peters³, Oreoluwa Oladiran³, Prem Parajuli³, Prakash Paudel⁴ and Anthony Donato³, ¹Reading Hospital-Tower Health System, West Reading, PA, ²Internal Medicine, Reading Hospital-Tower Health System, WEST READING, PA, ³Reading Hospital, West Reading, PA, ⁴Internal Medicine, Berkshire Medical Center, Pittsfield, MA
Background/Purpose: Selective Estrogen Receptor Modulators (SERMs) are one of the available treatment options for postmenopausal osteoporosis. Since Raloxifene was first introduced on 1997 for post-menopausal…
Abstract Number: 2814 • 2018 ACR/ARHP Annual Meeting
Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Fenglong Xie¹, Lang Chen¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) has been associated with reduced risk for cardiovascular disease (CVD) in several studies conducted among rheumatoid arthritis (RA) patients never exposed to…
Abstract Number: 2815 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Safety – Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials
Michael Weinblatt¹, Peter C. Taylor², Gerd R. Burmester³, Chadi Saifan⁴, Chad D. Walls⁴, Maher Issa⁴, Terence P. Rooney⁴ and Tsutomu Takeuchi⁵, ¹Brigham and Women’s Hospital, Boston, MA, ²Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ³Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Baricitinib (BARI), a selective inhibitor of Janus kinases, is approved in >40 countries for the treatment of active rheumatoid arthritis (RA) in adults. Patients…
Abstract Number: 2816 • 2018 ACR/ARHP Annual Meeting
Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis
Michelle J. Ormseth¹, Joseph F. Solus¹, Quanhu Sheng¹, Fei Ye¹, Yan Guo¹, Qiong Wu¹, Annette M. Oeser¹, Ryan Allen¹, Paolo Raggi², Kasey Vickers¹ and C Michael Stein¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Small noncoding RNAs (sRNAs), such as microRNAs (miRNAs), regulate gene expression and can be used as biomarkers of disease. Patients with rheumatoid arthritis (RA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].